Matinas BioPharma files IND with FDA for lead antibacterial development candidate MAT2501
Matinas BioPharma president and CEO Roelof Rongen said: "In preclinical studies, MAT2501 was shown to have oral bioavailability and provide targeted delivery of the powerful antibiotic, amikacin, directly
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.